Edition:
United States

ITUS Corp (ITUS.OQ)

ITUS.OQ on NASDAQ Stock Exchange Capital Market

3.18USD
22 Jun 2018
Change (% chg)

$0.13 (+4.26%)
Prev Close
$3.05
Open
$3.07
Day's High
$3.18
Day's Low
$3.00
Volume
46,508
Avg. Vol
47,533
52-wk High
$6.42
52-wk Low
$0.60

Chart for

About

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that... (more)
No analyst recommendations are available for .

Overall

Beta: -1.11
Market Cap(Mil.): $42.44
Shares Outstanding(Mil.): 15.32
Dividend: --
Yield (%): --

Financials

  ITUS.OQ Industry Sector
P/E (TTM): -- 26.96 24.63
EPS (TTM): -0.64 -- --
ROI: -75.74 9.24 7.25
ROE: -174.62 12.59 12.43

BRIEF-Itus Corp - Co Entered Into An At Market Issuance Sales Agreement With B. Riley FBR, Inc

* ITUS CORP - ‍ON MARCH 27, CO ENTERED INTO AN AT MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR, INC TO CREATE AN AT MARKET EQUITY PROGRAM​

Mar 27 2018

BRIEF-Itus And Serametrix Announce Results Of A Blinded Prostate Cancer Study

* ITUS AND SERAMETRIX ANNOUNCE RESULTS OF A BLINDED PROSTATE CANCER STUDY

Mar 27 2018

BRIEF-Itus Corp Forms Alliance With Serametrix Corp

* ITUS CORPORATION FORMS ALLIANCE WITH SERAMETRIX CORPORATION

Mar 05 2018

BRIEF-Lewis Titterton Reports 6.6 Pct Stake In Itus Corp As Of Feb. 14, 2018

* LEWIS H. TITTERTON REPORTS 6.6 PERCENT STAKE IN ITUS CORP AS OF FEBRUARY 14, 2018 - SEC FILING‍​ Source text (http://bit.ly/2CoeRLH) Further company coverage:

Feb 15 2018

Earnings vs. Estimates

No consensus analysis data available.